Axsome Therapeutics Inc’s filing revealed that its General Counsel Murdock Hunter R. unloaded Company’s shares for reported $0.77 million on Jun 20 ’25. In the deal valued at $102.47 per share,7,500 shares were sold. As a result of this transaction, Murdock Hunter R. now holds 0 shares worth roughly $0.0.
Then, Murdock Hunter R. sold 6,014 shares, generating $602,122 in total proceeds. Upon selling the shares at $100.12, the General Counsel now owns 0 shares.
Before that, Murdock Hunter R. bought 6,014 shares. Axsome Therapeutics Inc shares valued at $602,101 were divested by the Officer at a price of $100.12 per share.
A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early June with a ‘”an Outperform”‘ rating. Jefferies began covering AXSM with “Buy” recommendation on April 07, 2025. Deutsche Bank started covering the stock on February 11, 2025. It rated AXSM as “a Buy”.
Price Performance Review of AXSM
On Monday, Axsome Therapeutics Inc [NASDAQ:AXSM] saw its stock jump 1.95% to $107.5. Over the last five days, the stock has gained 4.01%. Axsome Therapeutics Inc shares have risen nearly 36.20% since the year began. Nevertheless, the stocks have risen 27.05% over the past one year. While a 52-week high of $139.13 was reached on 02/21/25, a 52-week low of $72.21 was recorded on 01/10/25.
Levels Of Support And Resistance For AXSM Stock
The 24-hour chart illustrates a support level at 105.30, which if violated will result in even more drops to 103.10. On the upside, there is a resistance level at 108.94. A further resistance level may holdings at 110.39.
How much short interest is there in Axsome Therapeutics Inc?
A steep rise in short interest was recorded in Axsome Therapeutics Inc stocks on 2025-06-13, growing by 0.13 million shares to a total of 4.02 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 3.89 million shares. There was a rise of 3.28%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 31, 2024 when Mizuho resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $122.
